The shares of CVS Health Corporation (NYSE:CVS) has been pegged with a rating of Neutral by Goldman in its latest research note that was published on November 29th, 2018. The research company has also assigned a $87 price target. Goldman wasn’t the only research firm that published a report of CVS Health Corporation, with other equities research analysts also giving their opinion on the stock. Evercore ISI advised investors in its research note published on November 28th, 2018, to Outperform the CVS stock while also putting a $89 price target. The stock had earned Peer Perform rating from Wolfe Research when it published its report on October 26th, 2018. The stock was given Buy rating by Citigroup in its report released on July 9th, 2018. BofA/Merrill was of a view that CVS is Buy in its latest report on February 27th, 2018. Citigroup thinks that CVS is worth Neutral rating. This was contained in the firm’s report on February 13th, 2018 in which the stock’s price target was also moved to $77.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 7 believe it has the potential for further growth, thus rating it as Hold while 8 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $93.10. The price of the stock the last time has raised by 27.32% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 43.85.
The shares of the company dipped by -2.97% during the trading session on Thursday, reaching a low of $73.89 while ending the day at $76.57. During the trading session, a total of 15.61 million shares were traded which represents a -86.55% decline from the average session volume which is 8.37M shares. CVS had ended its last session trading at 78.91. CVS Health Corporation currently has a market cap of $77.82B, while its P/E ratio stands at 48.99, while its P/E earnings growth sits at 0.41, with a beta of 0.97. CVS Health Corporation debt-to-equity ratio currently stands at 1.72, while its quick ratio hovers at 1.90. CVS 52-week low price stands at $60.14 while its 52-week high price is $83.88.
The company in its last quarterly report recorded $1.73 earnings per share which is above the $1.71 predicted by most analysts. The CVS Health Corporation generated $47,269.00 million in revenue during the last quarter, which is slightly higher than the $47,195.80 million predicted by analysts. In the second quarter last year, the firm recorded $1.69 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 2.31%. CVS Health Corporation has the potential to record 1.56 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Pivotal Research Group published a research note on October 15th, 2018 where it informed investors and clients that Walgreens Boots Alliance, Inc. (NASDAQ:WBA) is now rated as Hold. Their price target on the stock stands at $72. Evercore ISI also rated WBA as Initiated on November 28th, 2018, with its price target of $47 suggesting that WBA could down by -7.78% from its current share price. Even though the stock has been trading at $82.82/share, analysts expect it to surge higher by 0.14% to reach $76.95/share. It started the day trading at $83.565 and traded between $80.77 and $82.94 throughout the trading session.
A look at its technical shows that WBA’s 50-day SMA is 78.36 while its 200-day SMA stands at 69.37. The stock has a high of $86.31 for the year while the low is $59.07. The company’s P/E ratio currently sits at 16.81, while the P/B ratio is 3.11. The company’s average trading volume currently stands at 6.05M shares, which means that the short-interest ratio is just 3.84 days. Over the past seven days, the company moved, with its shift of -2.01%. Looking further, the stock has raised 21.92% over the past 90 days while it gained 30.41% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Vanguard Group Inc bought more WBA shares, increasing its portfolio by +0.68% during the last quarter. This move now sees The Vanguard Group Inc purchasing 466,901 shares in the last quarter, thus it now holds 69,397,351 shares of WBA, with a total valuation of $5,535,826,689. SSgA Funds Management Inc meanwhile bought more WBA shares in the recently filed quarter, changing its stake to $3,528,328,408 worth of shares. BlackRock Fund Advisors followed the path by decreasing its WBA portfolio by -1.06% in the quarter. This means that BlackRock Fund Advisors sold -366,418 shares in the last quarter and now controls 34,249,044 shares of the WBA stock, with the valuation hitting $2,732,046,240.
Similarly, Capital Research Management Co increased its Walgreens Boots Alliance, Inc. shares by +24.43% during the recently filed quarter. After buying 2,266,950 shares in the last quarter, the firm now controls 11,545,175 shares of Walgreens Boots Alliance, Inc. which are valued at $920,958,610. In the same vein, Wellington Management Co LLP decreased its Walgreens Boots Alliance, Inc. shares by during the most recent reported quarter. The firm sold -8,477,224 shares during the quarter which decreased its stakes to 11,303,119 shares and is now valued at $901,649,803. Following these latest developments, around 0.20% of Walgreens Boots Alliance, Inc. stocks are owned by institutional investors and hedge funds.